Cronos Group (CRON) Expected to Announce Earnings on Monday

Cronos Group (NASDAQ:CRON) is anticipated to announce its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $42.20 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 8:30 AM ET.

Cronos Group (NASDAQ:CRON) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01. The company had revenue of $58.39 million for the quarter, compared to the consensus estimate of $38.51 million. Cronos Group had a negative return on equity of 1.12% and a negative net margin of 6.44%.

Cronos Group Price Performance

CRON opened at $2.54 on Friday. Cronos Group has a one year low of $1.84 and a one year high of $3.43. The business has a 50 day simple moving average of $2.59 and a two-hundred day simple moving average of $2.60. The firm has a market capitalization of $955.73 million, a price-to-earnings ratio of -253.75 and a beta of 0.87.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group began coverage on Cronos Group in a research note on Tuesday, January 27th. They set a “buy” rating on the stock. TD Securities began coverage on shares of Cronos Group in a report on Tuesday, February 24th. They issued a “buy” rating on the stock. Weiss Ratings downgraded shares of Cronos Group from a “hold (c)” rating to a “sell (d+)” rating in a research report on Monday, March 2nd. Wall Street Zen upgraded shares of Cronos Group from a “sell” rating to a “hold” rating in a report on Sunday, March 8th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $2.30 target price on shares of Cronos Group in a research report on Wednesday, January 14th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $2.30.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Legal & General Group Plc grew its stake in Cronos Group by 16.1% in the second quarter. Legal & General Group Plc now owns 195,368 shares of the company’s stock worth $374,000 after purchasing an additional 27,111 shares during the period. Corient Private Wealth LLC lifted its position in Cronos Group by 35.0% during the second quarter. Corient Private Wealth LLC now owns 135,882 shares of the company’s stock valued at $260,000 after buying an additional 35,245 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Cronos Group by 192.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 89,683 shares of the company’s stock valued at $171,000 after buying an additional 59,013 shares in the last quarter. Virtu Financial LLC boosted its holdings in shares of Cronos Group by 10.4% during the 4th quarter. Virtu Financial LLC now owns 52,852 shares of the company’s stock valued at $139,000 after buying an additional 4,990 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its position in shares of Cronos Group by 291.6% in the 1st quarter. Jones Financial Companies Lllp now owns 65,099 shares of the company’s stock worth $118,000 after buying an additional 48,476 shares during the period. Hedge funds and other institutional investors own 8.71% of the company’s stock.

About Cronos Group

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.